Induction of IBV strain-specific neutralizing antibodies and broad spectrum protection in layer pullets primed with IBV Massachusetts (Mass) and 793B vaccines prior to injection of inactivated vaccine containing Mass antigen.

In an initial study in specified pathogen free (SPF) chickens, a heterologous virus neutralizing (VN) antibody response to IBV variants Q1, Variant 2 (Var 2), D388/QX (D388), D274 and Arkansas (DPI) was observed using a vaccination programme incorporating two different live-attenuated IBV vaccines, followed by boosting with an inactivated vaccine containing IBV Massachusetts (Mass) antigen. Therefore, a more detailed study was undertaken in SPF layer-type chickens primed with IBV Mass and 793B vaccines. The efficacy of single or repeated vaccination with a multivalent inactivated vaccine containing IBV antigen was determined against challenge with five virulent IBVs: Mass (M41), 793B (4/91), D388, Q1 and Var 2.

Alternative methods to compare safety of live-attenuated respiratory Newcastle disease vaccines in young chicks.

The work reported here is an initial attempt to find an alternative method by which the safety of live-attenuated Newcastle disease virus (NDV) vaccines for the respiratory tract of young chickens can be assessed. The current recommended methods involve either the subjective assessment of respiratory signs, or raise ethical concerns, as in the case of the intracerebral pathogenicity index. The two methods considered here were the use of tracheal organ cultures to assess the level of ciliostasis which the vaccines caused to the ciliated epithelium of the trachea and the incorporation of a pathogenic strain of in the inoculum in order to induce colibacillosis.

Efficacy of a new tetravalent coryza vaccine against emerging variant type B strains.

Outbreaks of infectious coryza have been reported in vaccinated flocks in different countries, indicating that new serotype(s) of Haemophilus paragallinarum may have evolved. Several field isolates from vaccinated flocks in the US, Ecuador, Argentina and Zimbabwe were examined and, apart from one serotype C strain, all were typed as serotype B. An inactivated commercial trivalent vaccine, containing serotypes A, B and C, protected against challenge with the serotype C isolate but protection against challenge with serotype B isolates was weaker, suggesting that they might represent a new variant immunotype.